Recent Trends in Sitagliptin Prescribing
Recent Trends in Sitagliptin Prescribing
During 2006–2007, a new prescription for sitagliptin was filled by 11,550 patients and for another OHA by 106,122 patients (Table 1). During 2008–2010, a new prescription for sitagliptin was filled by 31,085 patients and for another OHA by 129,117 patients. When the patient population was divided into four age groups and each group was evaluated for the number of patients receiving a new prescription for either sitagliptin or other OAHAs (Table 1), the youngest group, 25–39 years of age, contained the fewest patients and the lowest percentage of patients receiving new prescriptions for any OHA during both evaluation periods. The group with the largest number of patients and with the largest percentage of patients given a new prescription for any OHA was 50–59 years of age during both time periods. Patients in the oldest group, 60–64 years of age, were more likely to be given a new prescription for sitagliptin than for another OAHA in both time periods, although the odds ratio for being given a new prescription for sitagliptin, compared with the other agents was greater during the period 2006 through 2007 compared with 2008 through April 2010.
A greater proportion of the patients were male during both time periods, but neither gender was more likely to receive a new prescription for sitagliptin compared with other agents.
During both time periods, the majority of patients and a slightly greater proportion of sitagliptin patients had been diagnosed with T2DM previously (Table 1). The majority of patients being treated with sitagliptin were receiving other agents as well in dual or triple or greater regimens; however, a slightly greater proportion was treated with sitagliptin monotherapy in the later interval of 2008–2010.
During the earlier period evaluated, patients with blindness or macular oedema or retinopathy or hypertension or proteinuria were more likely to have received a new prescription for sitagliptin than for another OAHA (Table 1). During the later period, the increased likelihood of a new prescription for sitagliptin remained for patients with hypertension and proteinuria, and patients with neuropathy became more likely to be given a new prescription for sitagliptin compared with other OAHAs (Table 1).
Results
During 2006–2007, a new prescription for sitagliptin was filled by 11,550 patients and for another OHA by 106,122 patients (Table 1). During 2008–2010, a new prescription for sitagliptin was filled by 31,085 patients and for another OHA by 129,117 patients. When the patient population was divided into four age groups and each group was evaluated for the number of patients receiving a new prescription for either sitagliptin or other OAHAs (Table 1), the youngest group, 25–39 years of age, contained the fewest patients and the lowest percentage of patients receiving new prescriptions for any OHA during both evaluation periods. The group with the largest number of patients and with the largest percentage of patients given a new prescription for any OHA was 50–59 years of age during both time periods. Patients in the oldest group, 60–64 years of age, were more likely to be given a new prescription for sitagliptin than for another OAHA in both time periods, although the odds ratio for being given a new prescription for sitagliptin, compared with the other agents was greater during the period 2006 through 2007 compared with 2008 through April 2010.
A greater proportion of the patients were male during both time periods, but neither gender was more likely to receive a new prescription for sitagliptin compared with other agents.
During both time periods, the majority of patients and a slightly greater proportion of sitagliptin patients had been diagnosed with T2DM previously (Table 1). The majority of patients being treated with sitagliptin were receiving other agents as well in dual or triple or greater regimens; however, a slightly greater proportion was treated with sitagliptin monotherapy in the later interval of 2008–2010.
During the earlier period evaluated, patients with blindness or macular oedema or retinopathy or hypertension or proteinuria were more likely to have received a new prescription for sitagliptin than for another OAHA (Table 1). During the later period, the increased likelihood of a new prescription for sitagliptin remained for patients with hypertension and proteinuria, and patients with neuropathy became more likely to be given a new prescription for sitagliptin compared with other OAHAs (Table 1).
Source...